This guidance is the result of FDA observations in the recent years involving significant breaches in product, clinical, and quality data integrity that directly placed patient safety at risk.
The FDA expects that data be reliable and accurate. CGMP regulations and guidance allow for flexible and risk-based strategies to prevent and detect data integrity issues. Firms are directed to implement meaningful and effective strategies to manage their data integrity risks based upon their process understanding and knowledge management of technologies and business processes.
